Title
Category
Credits
Event date
Cost
The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
  • CMHC
  • TME
  • 0.75 ACPE Pharmacy
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC
  • 0.75 Participation
$0.00
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects an estimated 25-30% of people in the United States and can often progress to Metabolic dysfunction-associated steatohepatitis (MASH) and cirrhosis. MASH represents a metabolic-driven array of multi-organ pathology that intersects with obesity, prediabetes, type 2 diabetes, and cardiovascular ailments. Many agents are currently in development for treatment of MASH, including glucagon-like peptide-1 receptor agonists (GLP1-Ras).
According to the Patient: Alopecia Areata in Adolescence
  • LivDerm
  • TME
  • 1.00 AAPA Category I CME
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
$0.00
The management of AA in adolescents presents various challenges to dermatology professionals, including identification of AA, limited effective treatment options, and high disease burden. Because hair loss has a significant physical and psychological impact on a child’s development, early diagnosis and treatment are essential. Currently there is only one systemic therapy approved for adolescents; however, there are additional therapies on the horizon with promising data.
Advances in Non-Steroidal Topicals: PDE-4 Inhibitors for Seborrheic Dermatitis and Beyond
  • LivDerm
  • TME
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC
  • 0.75 Participation
$0.00
Traditional treatments for seborrheic dermatitis, including oral and topical steroids, present a variety of challenges including lack of efficacy, adverse events with long-term use, limitations for adherence, and the inability to treat both hair- and non-hair-bearing areas. Recently, the first targeted therapy for treatment of seborrheic dermatitis, a PDE-4 inhibitor topical foam, was approved by the FDA.
Psoriasis in Skin of Color Unplugged: Addressing the Barriers to Patient Care and Relief
  • LivDerm
  • TME
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
$0.00
Various gaps in the management of psoriasis patients with skin of color (SOC) persist due to a lack of training on SOC and inherent barriers to care. As a result, psoriasis patients with SOC are often misdiagnosed, experience more severe disease, and experience more disease burden. Recent clinical trial data supports the need for nuanced care when treating psoriasis patients with SOC using systemic agents. It is important that clinicians are able to identify treatment barriers and develop strategies to address these barriers and personalize care.
A New Wave of Topical Therapies for Atopic Dermatitis: Comparing Treatment Approaches
  • LivDerm
  • TME
  • 1.00 AANP
  • 1.00 AAPA Category I CME
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
$0.00
Topical therapies are considered the mainstay treatment for atopic dermatitis (AD). However, traditional topicals such as corticosteroids and calcineurin inhibitors are associated with limitations for use and safety concerns. In addition, treatment guidelines for AD provide few to no recommendations for selecting therapies and, as a result, treatment selection for each patient can be complex and subjective. New targeted topical therapies are becoming increasingly available, and clinicians must be familiar with the latest clinical data and how to utilize them in clinical practice.